Ducharme O, Beylot-Barry M, Pham-Ledard A, et al. - Considering that PCLBCL-LT's mutational profile has highlighted mutations that lead to constitutive NF-κB and B-cell receptor (BCR) signaling pathways but has not displayed clinical utility, researchers determined the mutational status of 32 patients with PCLBCL-LT (14 patients with complete durable response and 18 patients with relapsing or refractory disease) with a dedicated lymphopanel. According to longitudinal analyses, MYD88 and CD79B were the earliest and among the most mutated genes. In patients with PCLBCL-LT, assessing BCR mutations may help to anticipate first-line therapeutic response and to select targeted therapies.